Focused on decoding the gene programs that drive HLH-like immune amplification.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Immune Effector Cell-associated HLH-like Syndrome (IEC-HS) represents a severe form of immune dysregulation often triggered by potent immune cell-based therapies, including CAR-T and TCR-engineered cells. While phenotypic and cytokine assessments provide critical immunological snapshots, genomic profiling unlocks a deeper mechanistic understanding by identifying gene-level changes that underlie immune activation, inflammatory circuit engagement, and dysregulated cell death pathways.
At Creative Biolabs, we offer a specialized IEC-HS Genomic Testing Service to support molecular interrogation of HLH-like events in adoptive cell therapy studies. Our genomic testing platform is designed to reveal transcriptional drivers, pathway activation states, and potential genetic predispositions in both effector and responder immune compartments, contributing to a more precise dissection of IEC-HS pathogenesis in experimental models.
Our IEC-HS Genomic Testing Service offers a suite of molecular assays tailored for immune-related genomic analysis. The service is compatible with a broad range of experimental models and sample types, enabling multi-layered insight into IEC-HS initiation and escalation.
Focused on decoding the gene programs that drive HLH-like immune amplification.
Validated workflows for human and mouse models, in vitro systems, and mixed-species settings.
Dissects intra-population variability and emergent immune phenotypes relevant to HLH-like pathology.
Gene lists, pathways, and outputs tailored to your CAR construct, model system, or research goal.
Results contextualized by immunologists with experience in CAR-T toxicology, not just raw bioinformatics.
Q1: Can I use this service with mouse models of HLH?
A1: Yes. We support both human and murine assays, including RNA-Seq and targeted panels specific to HLH-related inflammation.
Q2: How does this service differ from standard RNA-Seq?
A2: Our pipeline emphasizes immune-related analysis, focusing on HLH-relevant cytokines, cytotoxicity markers, and pathway scores critical to IEC-HS interpretation.
Q3: Is scRNA-seq necessary for every project?
A3: Not necessarily. For bulk-level profiling, targeted panels or conventional RNA-Seq are often sufficient unless high-resolution subset analysis is needed.
Q4: How much RNA do I need to provide?
A4: For standard bulk RNA-Seq, a minimum of 100 ng of high-quality total RNA is recommended. For scRNA-seq, viable single-cell suspensions are required.
Q5: Can results be combined with cytokine or flow cytometry data?
A5: Absolutely. We specialize in multi-omic integration and can align gene expression trends with cellular phenotypes and secreted factor profiles.
Creative Biolabs leverages advanced genomic technologies to illuminate the transcriptional underpinnings of HLH-like responses during CAR-T cell studies. Whether you're profiling activation circuits, assessing intervention effects, or seeking predictive biomarkers, our IEC-HS Genomic Testing Service offers the resolution and precision needed to power next-generation immunotoxicity investigations.
Let us help you decode the genomic blueprint of IEC-HS-related immune dysregulation.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
